Sharma R, Gulati A, Chopra K
Eur J Clin Pharmacol. 2025; .
PMID: 40080138
DOI: 10.1007/s00228-025-03822-w.
Wheaton L, Bujkiewicz S
Int J Technol Assess Health Care. 2025; 41(1):e11.
PMID: 39967232
PMC: 11894387.
DOI: 10.1017/S0266462325000017.
Baldwin D, Carmichael J, Cook G, Navani N, Peach J, Slater R
Cancer Manag Res. 2024; 16:791-810.
PMID: 39044745
PMC: 11264281.
DOI: 10.2147/CMAR.S441359.
Manyara A, Davies P, Stewart D, Weir C, Young A, Blazeby J
BMJ. 2024; 386:e078524.
PMID: 38981645
PMC: 11231881.
DOI: 10.1136/bmj-2023-078524.
Manyara A, Davies P, Stewart D, Weir C, Young A, Blazeby J
BMJ. 2024; 386:e078525.
PMID: 38981624
PMC: 11231880.
DOI: 10.1136/bmj-2023-078525.
Using Bayesian Evidence Synthesis Methods to Incorporate Real-World Evidence in Surrogate Endpoint Evaluation.
Wheaton L, Papanikos A, Thomas A, Bujkiewicz S
Med Decis Making. 2023; 43(5):539-552.
PMID: 36998240
PMC: 10336701.
DOI: 10.1177/0272989X231162852.
Experimental Medicine Approaches in Early-Phase CNS Drug Development.
English B, Ereshefsky L
Adv Neurobiol. 2023; 30:417-455.
PMID: 36928860
DOI: 10.1007/978-3-031-21054-9_17.
The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status.
Poad H, Khan S, Wheaton L, Thomas A, Sweeting M, Bujkiewicz S
Cancers (Basel). 2022; 14(21).
PMID: 36358810
PMC: 9654686.
DOI: 10.3390/cancers14215391.
Systemic therapy for early-stage breast cancer: learning from the past to build the future.
Agostinetto E, Gligorov J, Piccart M
Nat Rev Clin Oncol. 2022; 19(12):763-774.
PMID: 36253451
PMC: 9575647.
DOI: 10.1038/s41571-022-00687-1.
Value Insider Season 1 Episode 1: The Importance of Payers and HTA: How Did We End Up Here? (Introduction to Value) [Podcast].
Drummond M, Hartgers-Gubbels E, Chambers M
Int J Gen Med. 2022; 15:7487-7492.
PMID: 36213303
PMC: 9532943.
DOI: 10.2147/IJGM.S389025.
Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments.
Trapani D, Tay-Teo K, Tesch M, Roitberg F, Sengar M, Altuna S
Curr Oncol. 2022; 29(8):5774-5791.
PMID: 36005193
PMC: 9406873.
DOI: 10.3390/curroncol29080455.
Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020.
Zhang Y, Naci H, Wagner A, Xu Z, Yang Y, Zhu J
JAMA Netw Open. 2022; 5(8):e2225973.
PMID: 35947385
PMC: 9366546.
DOI: 10.1001/jamanetworkopen.2022.25973.
Aspiring to Reasonableness in Accelerated Approval: Anticipating and Avoiding the Next Aducanumab.
Largent E, Peterson A, Karlawish J, Lynch H
Drugs Aging. 2022; 39(6):389-400.
PMID: 35696021
PMC: 9247014.
DOI: 10.1007/s40266-022-00949-8.
For Whom the Price Escalates: High Price and Uncertain Value of Cancer Drugs.
Shin G, Kwon H, Bae S
Int J Environ Res Public Health. 2022; 19(7).
PMID: 35409887
PMC: 8998346.
DOI: 10.3390/ijerph19074204.
Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis.
Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C
BMJ. 2021; 375:e066381.
PMID: 34933868
PMC: 8689398.
DOI: 10.1136/bmj-2021-066381.
